Raymond James Maintains Strong Buy on CymaBay Therapeutics, Raises Price Target to $34
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Steven Seedhouse maintains a Strong Buy rating on CymaBay Therapeutics (NASDAQ:CBAY) and raises the price target from $33 to $34.
November 08, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James maintains a Strong Buy rating on CymaBay Therapeutics and raises the price target from $33 to $34.
The news of Raymond James maintaining a Strong Buy rating and raising the price target for CymaBay Therapeutics is likely to instill confidence in investors and could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100